Relmada Therapeutics Inc (RLMD NASDAQ) stock market data APIs
$4.2317
-0.19(-4.5%)
as of December 5, 2025
Try our APIs with
free plan!
Relmada Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. It also develops REL-P11, a modified-release formulation of psilocybin that has completed Phase 1 safety study for the treatment of metabolic disease. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
Prev. Close
4.2317
Open
4.0451
High
4.3193
Low
3.981
52 wk Range
0.2404-5.12
Market Cap
331 M
Shares Outstanding
73 334 K
EPS
-0.304
Beta
0.833
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Relmada Therapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Relmada Therapeutics Inc data using free add-ons & libraries
Get Relmada Therapeutics Inc Fundamental Data
Relmada Therapeutics Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -161 247 824
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-06
- EPS/Forecast: -0.45
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Relmada Therapeutics Inc News
New
Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology
Poster highlights 6-month follow-up data from the ongoing Phase 2 trial of NDV-01 in non-muscle invasive bladder cancer (NMIBC), with favorable overall safety Relmada plans to advance NDV-01, a susta...
This Stock Is Up 704% in 2025 But Has No Products to Its Name
Relmada Therapeutics (RLMD) is a clinical-stage pharma company with no commercialized products and a $141 million market cap. RLMD has shown strong technical momentum, gaining 440% since August. Share...
Relmada signals 2026 launch of two pivotal studies for NDV-01 and sepranolone, supported by $100M financing
Earnings Call Insights: Relmada Therapeutics (RLMD) Q3 2025 MANAGEMENT VIEW * CEO Sergio Traversa highlighted a "standout year" for Relmada, citing "excellent product development progress" and a "...
Relmada Therapeutics Reports Third Quarter 2025 Financial Results and Provides Key Clinical, Regulatory, and Corporate Updates
Positive 9-month follow-up data for NDV-01 showed a 92% overall response rate at any time in non-muscle invasive bladder cancer (NMIBC), with favorable overall safety Secured FDA alignment on key ele...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
